Business Wire

Debiopharm Joins Discussions With International Health Organisations to Fight Anti-Microbial Resistance at the 2023 World AMR Congress


Debiopharm (, a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced their participation in the keynote panel and antibiotic development track sessions at the 2023 World AMR conference from September 7th – 8th, 2023.

Debiopharm’s panelist Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, is part of the AMR preparedness keynote panel to be moderated by Bruce Y. Lee from Forbes and involving representatives from the CDC, Menarini Group, IFPMA and the AMR Action Fund. A further Debiopharm-sponsored breakout session, moderated by Dr. Ricardo Chaves, Executive Medical Director, will feature Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion at the CDC, explaining the relevance of novel microbiome-sparing antibiotics in combating AMR, and the potential need for new regulatory approval and reimbursement pathways.*

“It’s important to harness these open dialogues between public organizations and the infectious disease industry experts at World AMR to produce action that can prepare us to face the emerging wave of resistant infections,” explained Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm. “We know that uncontrollable infectious diseases are everybody’s business, and that our preparation efforts must involve the reinforcement of prevention measures, better stewardship education, and sustainable market pathways for new effective treatments.”

“The CDC recognizes the importance of the human microbiome as it provides key resistance to human colonization with multidrug-resistant pathogens. Along with products that will reduce the degree of colonization (i.e. pathogen reduction), or drugs that will restore the microbiome, we need therapeutic antibiotics that spare the microbiome, by being highly-selective for only specific pathogens.” expressed Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion, CDC.

Last year’s special report from the CDC on the impact of COVID-19 on antimicrobial resistance revealed that 6 of the 18 most alarming bacterial menaces cost the US more that $4.6 billion each year and thousands of human lives.4 The agency’s 18 bacterial and fungal threats include 2 pathogens for which Debiopharm is currently developing new antibiotics: Neisseria gonorrhoeae and methicillin-resistant Staphylococcus aureus. Debiopharm’s FabI inhibitor therapies are part of a new pathogen-specific antibiotic class that is being researched for its capacity to effectively treat a single type of bacteria and thereby preserve the microbiome and avoid subsequent spread of AMR.

World AMR 2023 Session details

Congress agenda



Keynote panel

Sept. 7th

08:35 EST



How can we push AMR to the forefront of preparedness?


Morgane Vanbiervliet,

Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm

+ other invited speakers



Panel discussion

Sept. 7th

11:00–11:30 EST




Antibiotic Development stream


The public health case for microbiome-sparing antibiotics: Potential need for new pathways in regulatory approval and reimbursement



Dr. Ricardo Chaves

Executive Medical Director




Dr.L. Clifford McDonald,

Associate Director for Science in the Division of Healthcare Quality Promotion, CDC



About afabicin

Afabicin (Debio 1450) is Debiopharm’s first-in-class FabI inhibitor against Staphylococcus spp., whose methicillin-resistant Staphylococcus aureus (MRSA) strains are high on the WHO global priority pathogen list and deemed a “serious threat” by the CDC. Afabicin can be administered orally or IV and selectively targets Staphylococcus ’ essential bacterial fatty acid biosynthesis. Promising results have been obtained in a comparative double-blind Phase 2 trial with afabicin in acute bacterial skin and skin structure infections. Currently, a Phase 2 trial in bone and joint infections is being conducted in several countries comparing afabicin to standard antibiotics.

About Debio 1453

Analogous to afabicin, the preclinical compound Debio 1453 is a potential first in class pathogen-specific drug targeting the essential bacterial fatty acid biosynthesis pathway. Debio 1453 is administered orally to treat Neisseria gonorrhoeae , the bacteria causing the sexually transmitted disease gonorrhea, a cause of serious and permanent health issues including infertility, ectopic pregnancy, cardiovascular and neurological problems.

Debiopharm’s fight against antimicrobial resistance

Debiopharm, an innovation-focused, Swiss biopharmaceutical company is one of the few privately owned companies developing novel class antibiotics to combat hard-to-treat infections. Through their unique partnership-based business model, the company is advancing pathogen-specific antibiotics from early stage through phase II clinical research with afabicin, specifically targeting staphylococci, being the most clinically advanced for the treatment of bone and joint infections. As a result of high selectivity, FabI inhibitors specifically target selected pathogens while preserving intestinal microbiota and meet all four WHO 2020 innovation criteria: new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes.

For more information, please visit

We are on Twitter. Follow us @DebiopharmNews at


[1] Morrison L, Zembower TR. Antimicrobial resistance. Gastrointest Endosc Clin N Am. 2020 Oct;30(4):619-635.

[2] Antimicrobial resistance surveillance in Europe 2023–2021 data.

[3] CDC Antibiotic resistance threats in the United States, 2019.

[4] COVID-19 U.S. Impact on Antimicrobial Resistance.


* Speaker disclosures: Dr. McDonald has no relevant financial or non-financial relationships to disclose. The findings and conclusions of this presentation are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services. Any use of trade names and commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Debiopharm Contact
Dawn Bonine
Head of Communication
Tel: +41 (0)21 321 01 11

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses21.9.2023 17:00:00 EEST | Press release

Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS) disorders, and viral barrier indications, to conduct preclinical studies in support of their development of quaternary ammonium palmitoyl glycol chitosan (GCPQ, under the trade name of AnQlar™). AnQlar is a nanoparticle intended to help prevent the spread of negatively charged viruses such as COVID-19 and influenza via intranasal spray, and has shown to inhibit the ability of the virus to replicate at non-toxic concentrations. In development since 2022, the project has so far seen the completion of safety assessment utilizing intranasal administration at Altasciences’ preclinical site in Columbia, MO. A cardiovascular study was also completed at Altasciences’ preclinical facility in Scranton, PA. Bioanalytical sample analysis for the GLP studies is currently ongoing. “We

Nitek: End of the Road for Copycats21.9.2023 16:00:00 EEST | Press release

Nitek, Inc. (“Nitek”), a pioneering American company in UV LEDs, has announced that it filed a patent infringement lawsuit against Photon Wave Co., Ltd. (“Photon Wave”), a Korean UV LED manufacturer in the Eastern District of Texas. In the complaint, Nitek asserts that LED products of ams OSRAM, a German LED company, use Photon Wave’s infringing LEDs. Nitek also contends that Photon Wave has failed to cease selling infringing products, even after getting continuous warning notices of the patent infringement, and therefore Nitek is not only seeking a permanent injunction against the sales of infringing products but also pursuing 3 times damages for willful patent infringement. Nitek has previously successfully won its patent lawsuit against another international LED maker, and continues its enforcement against other infringers. Sensor Electronic Technology, Inc. (“SETi”), an affiliate of Nitek, has also obtained a permanent injunction for patent infringement against Bolb, Inc., a UV LED

Boomi Launches World Tour, Bringing Together Visionary Leaders and Industry Experts to Prepare Businesses for the AI Revolution21.9.2023 16:00:00 EEST | Press release

Boomi™, the intelligent connectivity and automation leader, today announced the Boomi World Tour, a premiere series of exclusive, in-person events bringing together Boomi customers, prospects, and partners to hear directly from Boomi leadership, industry experts, and visionaries on how organizations can leave complexity behind and synchronize everything, everywhere, with AI-driven integration and automation. This press release features multimedia. View the full release here: Boomi Launches World Tour, Bringing Together Visionary Leaders and Industry Experts to Prepare Businesses for the AI Revolution (Graphic: Business Wire) The Boomi World Tour is a series of 10 events over eight weeks, including three Partner Summits designed especially for Boomi partners, global systems integrators, and OEMs. The tour kicks off in Menlo Park, CA, October 3-4, 2023, where attendees will have opportunities to connect and learn throughout the tw

Hologic and Bayer Announce International Partnership to Deliver Comprehensive Contrast-Enhanced Mammography Package to Breast Imaging Facilities21.9.2023 15:30:00 EEST | Press release

Hologic Inc. (Nasdaq: HOLX) and Bayer today announced an international partnership to deliver contrast-enhanced mammography (CEM) solutions to improve the detection of breast cancer for women in multiple countries across the European, Canadian and Asia Pacific regions. CEM is a highly sensitive and relatively low-cost breast imaging modality that combines digital mammography with the administration of a contrast agent to support breast cancer diagnosis and guide treatment decisions.1 The partnership brings together the companies’ leading technologies (Hologic mammography gantries and Bayer CEM-approved injection systems) to enable the administration of contrast media during a mammography examination. With the new agreement, Bayer and Hologic aim to optimally support radiologists and their teams’ needs by providing a comprehensive product package along with the hands-on training needed to effectively implement CEM into their facility’s workflow. “Over the past several years, we’ve seen

ReNAgade Therapeutics Named to the 2023 Endpoints 1121.9.2023 15:00:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that it has been named as one of the Endpoints 11 companies of 2023, awarded by Endpoints News editor John Carroll to the most promising private biotechnology companies in the industry. “To be included as one of the Endpoints 11 top private biotech companies is not only a great honor for our young company, but also recognition from the industry of what we’ve already accomplished in the past 18 months toward our aim of overcoming the current limitations of RNA medicines,” said Amit D. Munshi, Chief Executive Officer of ReNAgade. “The Company has continued to grow since our $300 million Series A financing round, building on our world-class, multidisciplinary team that is dedicated to innovating delivery technology and bringing an array of genomic medicine tools under one roof. We look forward to expanding the reach of RNA medicine beyond what was previously thought possible, beginning wi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom